Showing 1761-1770 of 2050 results for "".
- Nanoscope’s Optogenetic Gene Therapy Restores Clinically Meaningful Vision in 11 Patients Blinded by Retinitis Pigmentosahttps://modernod.com/news/nanoscopes-optogenetic-gene-therapy-restores-clinically-meaningful-vision-in-11-patients-blinded-by-retinitis-pigmentosa/2479261/Nanoscope Therapeutics announced that vision improvements for all evaluated advanced retinitis pigmentosa (RP) patients persisted through 1 year following a single intravitreal injection in a phase 1/2a clinical study with MCO. “We expect to begin the first randomized, placebo-contro
- CooperVision DreamLite Ortho-K Lenses Gain European Approval for Slowing Progression of Myopiahttps://modernod.com/news/coopervision-dreamlite-ortho-k-lenses-gain-european-approval-for-slowing-progression-of-myopia/2479240/CooperVision Specialty EyeCare’s Procornea DreamLite night lenses have received European approval for slowing the progression of myopia in children and young adults. The orthokeratology contact lens is the latest CooperVision myopia control product to gain the CE Mark, joining EyeDream and Parago
- EU Signs Deal With BioNTech, Pfizer for Further 1.8 Billion COVID-19 Vaccine Doseshttps://modernod.com/news/eu-signs-deal-with-biontech-pfizer-for-further-1-8-billion-covid-19-vaccine-doses/2479234/The European Commission announced the signing of a third contract with BioNTech and Pfizer for the supply of up to 1.8 billion COVID-19 vaccine doses between the end of this year and 2023, according to a FirstWord report. The deal, which had been agreed earlier this month, allows for the purchase
- CDC Endorses Use of Pfizer, BioNTech COVID-19 Vaccine in Teens as Young as 12https://modernod.com/news/cdc-endorses-use-of-pfizer-biontech-covid-19-vaccine-in-teens-as-young-as-12/2479204/An advisory panel of the US Centers for Disease Control and Prevention (CDC) on Wednesday voted 14-0, with one recusal, to endorse the FDA’s recent decision to extend use of Pfizer and BioNTech’s COVID-19 vaccine BNT162b2 to 12- to 15-year-olds, according to FirstWord. The recommendat
- Gemini Therapeutics Completes Enrollment in Phase 2a Study of GEM103 as an Add-On to Anti-VEGF Therapy for the Treatment of Wet AMDhttps://modernod.com/news/gemini-therapeutics-completes-enrollment-in-phase-2a-study-of-gem103-as-an-add-on-to-anti-vegf-therapy-for-the-treatment-of-wet-amd/2479205/Gemini Therapeutics announced the completion of enrollment in its phase 2a trial advancing GEM103 as a potential add-on therapy for patients suffering from wet AMD and requiring continued anti-vascular endothelial growth factor (anti-VEGF) treatment who have, or may be at risk for, macular atroph
- Euclid Systems Launches New Euclid MAX Ortho-K Lenshttps://modernod.com/news/euclid-systems-launches-new-euclid-max-ortho-k-lens/2479200/Euclid Systems announced the United States launch of the overnight orthokeratology lens Euclid MAX. Used in children and adult patients with progressive myopia, but especially children, Ortho-K contact lenses gently reshape the cornea to manage myopia while the patient sleeps. “Euclid MAX
- Johnson & Johnson Vision Announces FDA Approval of Acuvue Abiliti Overnight Therapeutic Lenses for Myopia Managementhttps://modernod.com/news/johnson-johnson-vision-announces-fda-approval-of-acuvue-abiliti-overnight-therapeutic-lenses-for-myopia-management/2479199/Johnson & Johnson Vision Care announced that the FDA has approved Acuvue Abiliti-Overnight Therapeutic Lenses. This is the first and only FDA approved orthokeratology (ortho-k) contact lens for the management of myopia. “The FDA approval of Abiliti Overnight marks an
- Innovega’s eMacula System Shows Potential to Increase Independence for Visually Impairedhttps://modernod.com/news/innovegas-emacula-system-shows-potential-to-increase-independence-for-visually-impaired/2479190/The use of Innovega eMacula system, which pairs smart contact lenses with display eyewear, demonstrated positive results with partially sighted subjects for their daily tasks, including reading, smart phone use, and distance vision, according to research conducted at The Ohio
- Belkin Laser Completes Enrollment of its GLAUrious Pivotal Trial for Glaucoma Laser Treatment in Secondshttps://modernod.com/news/belkin-laser-completes-enrollment-of-its-glaurious-pivotal-trial-for-glaucoma-laser-treatment-in-seconds-2/2479186/Belkin Laser announced that it has completed enrollment in its GLAUrious randomized controlled trial. In this confirmatory, prospective, noninferiority, observer masked RCT a total of 192 patients were randomized across two arms, SLT and DSLT. Six-month follow up for primary endpoint is expected
- Johnson & Johnson Vision Announces FDA Approval Of Tecnis Synergy And Tecnis Synergy Toric II IOLs In the UShttps://modernod.com/news/johnson-johnson-vision-announces-the-approval-of-tecnis-synergy-and-tecnis-synergy-toric-ii-iols-in-the-us/2479178/Johnson & Johnson Vision announced the FDA approval of Tecnis Synergy and Tecnis Synergy Toric II IOLs, and the Health Canada approval of Tecnis Synergy Toric II IOLs. This next-generation PCIOL is built on the legacy Tecnis platform and delivers a wide range of continuous vision with